Trial Profile
A Phase 1b Study of JCAR014, Autologous T Cells Engineered to Express a CD19-Specific Chimeric Antigen Receptor, in Combination With Durvalumab (MEDI4736) for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 30 Oct 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; JCAR 014 (Primary) ; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
- 13 Dec 2022 Results assessing the safety of JCAR-014 in combination of Durvalumab presented at the 64th American Society of Hematology Annual Meeting and Exposition.
- 29 Mar 2022 Status changed from active, no longer recruiting to discontinued.
- 24 Jun 2021 Status changed from recruiting to active, no longer recruiting.